PTCT - PTC Therapeutics, Inc.
PTC Therapeutics, Inc.
100 Corporate Court
South Plainfield, NJ 07080
United States
908 222 7000
https://www.ptcbio.com
Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 1,402
Key executives
| Name | Title | Pay | Exercised | Year born |
|---|---|---|---|---|
| Dr. Matthew B. Klein F.A.C.S., FACS, M.D., M.S., MS | CEO & Director | 995.4k | N/A | 1972 |
| Dr. Stuart W. Peltz Ph.D. | Co-Founder, Sr. Consultant & Member of Scientific Advisory Board | 1.54M | N/A | 1960 |
| Dr. Allan Steven Jacobson Ph.D. | Co-Founder, Chairman of Scientific Advisory Board & Independent Director | 145k | N/A | 1946 |
| Dr. Neil Almstead Ph.D. | Chief Technical Operations Officer | 829.97k | N/A | 1967 |
| Mr. Eric Pauwels | Chief Bus. Officer | 847.67k | N/A | 1961 |
| Ms. Christine Utter | Sr. VP, Chief Accounting Officer & Head of People Services | N/A | N/A | 1978 |
| Ms. Ellen Welch Ph.D. | Chief Scientific Officer | N/A | N/A | N/A |
| Alex Kane | Investor Relations Officer | N/A | N/A | N/A |
| Mr. Mark Elliott Boulding | Exec. VP & Chief Legal Officer | N/A | N/A | 1961 |
| Ms. Jane Baj | VP of Corp. Communications | N/A | N/A | N/A |
Description
PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders. Its portfolio pipeline includes commercial products and product candidates in various stages of development, including clinical, pre-clinical and research and discovery stages, focuses on the development of treatments for multiple therapeutic areas, such as rare diseases. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy in the European Economic Area and the United States, as well as to treat nonsense mutation Duchenne muscular dystrophy in Brazil and Russia; commercializes Tegsedi and Waylivra for the treatment of rare diseases in Latin America and the Caribbean; and markets Evrysdi for the treatment of spinal muscular atrophy in adults and children two months and older in Brazil. The company's splicing platform includes PTC518, which is being developed for the treatment of Huntington's disease; bio-e platform, such as vatiquinone and utreloxastat; metabolic platform comprising sepiapterin; gene therapy platform, including an asset targeting Friedreich ataxia; oncology platform, such as Unesbulin; and other multi-platform. PTC Therapeutics, Inc. has collaborations with F. Hoffman-La Roche Ltd and Hoffman-La Roche Inc., as well as the Spinal Muscular Atrophy Foundation to advance drug discovery and development research in regenerative medicine; and Akcea Therapeutics, Inc. to commercialize Tegsedi and Waylivra for the treatment of rare diseases in Latin America and the Caribbean. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in South Plainfield, New Jersey.
Corporate governance
PTC Therapeutics, Inc.’s ISS governance QualityScore as of 1 June 2023 is 5. The pillar scores are Audit: 6; Board: 2; Shareholder rights: 7; Compensation: 6.
